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Trials have provided conflicting estimates of the risk of gastrointestinal illness attributable to tap water. To
estimate this risk in an Iowa community with a well-run water utility with microbiologically challenged source
water, the authors of this 2000–2002 study randomly assigned blinded volunteers to use externally identical
devices (active device: 227 households with 646 persons; sham device: 229 households with 650 persons) for 6
months (cycle A). Each group then switched to the opposite device for 6 months (cycle B). The active device
contained a 1-Pm absolute ceramic filter and used ultraviolet light. Episodes of “highly credible gastrointestinal
illness,” a published measure of diarrhea, nausea, vomiting, and abdominal cramps, were recorded. Water usage
was recorded with personal diaries and an electronic totalizer. The numbers of episodes in cycle A among the
active and sham device groups were 707 and 672, respectively; in cycle B, the numbers of episodes were 516
and 476, respectively. In a log-linear generalized estimating equations model using intention-to-treat analysis, the
relative rate of highly credible gastrointestinal illness (sham vs. active) for the entire trial was 0.98 (95%
confidence interval: 0.86, 1.10). No reduction in gastrointestinal illness was detected after in-home use of a
device designed to be highly effective in removing microorganisms from water.
drinking; epidemiologic studies; gastrointestinal diseases; intervention studies; randomized controlled trials;
water; water supply

Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval; EPA, US Environmental Protection
Agency; HCGI, highly credible gastrointestinal illness.

Although infectious disease outbreaks can result from
mistakes in the management of drinking water systems, there
are questions regarding the extent to which such illness can
be attributed to drinking water in systems that operate
properly (1, 2). Previous drinking water trials produced
conflicting results (3–6). In 1996, the US Congress amended
the Safe Drinking Water Act (7). One of the Act’s provisions
that focuses on the above uncertainties (Section 1458 (d) (1))

required the Centers for Disease Control and Prevention
(CDC) and the US Environmental Protection Agency (EPA)
to conduct studies on waterborne disease occurrence and to
provide a national estimate of waterborne disease. After a
lengthy public discussion and planning process (8, 9), the
CDC and the EPA funded a pilot and a large-scale drinking
water trial as well as several smaller studies to estimate the
risk of illness from using municipal tap water.

Correspondence to Dr. John M. Colford, Jr., University of California, Berkeley, School of Public Health, Division of Epidemiology and Public
Health Biology, 140 Warren Hall #7360, Berkeley, CA 94720 (e-mail: jcolford@socrates.berkeley.edu).
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MATERIALS AND METHODS

The study and the informed consent process were
reviewed, approved, and monitored by institutional review
boards at the University of California, Berkeley; the CDC;
the EPA; the state of California; and Public Health Foundation Enterprises of Los Angeles, California.
Active and sham water treatment devices and
installation

Point-of-use devices for the trial were solicited in a
national bid with more than 20 respondents and were
selected to maximize microbial disinfection while minimizing effects on taste and chemical properties. On the basis
of our experience in the pilot study (6), countertop units were
chosen to minimize difficulties with installation and use.
We selected 1-Pm filtration and ultraviolet treatment to
reduce potential microbial contamination with minimal
effect on taste and other qualities of the water. Unlike
reverse osmosis devices and devices that use carbon filtration, the device that was used does not change the chemical
composition of the water. This characteristic was desirable
to maintain participant blinding.
The device selected was designed and manufactured by a
firm selling similar devices in domestic and international
markets. The active device consisted of a 1-Pm ceramic
prefilter and ultraviolet treatment with an output of 35,000–
38,000 PW-second/cm2. Except for replacement of the
pressed activated carbon block filter with a ceramic 1-Pm
filter (to avoid noticeable changes in the water’s taste and
odor usually associated with the use of carbon filters), the
device is identical to a commercially available model (class
A) certified by the National Sanitary Foundation (model E8301J; Amway Access Business Group, Ada, Michigan),
used extensively in Asia. The installed devices were rectangular, with approximate dimensions of 5 1/2 (13.34 cm)
inches wide by 8 inches (20.32 cm) long by 11 1/2 inches
(29.21 cm) high. A diverter was attached to the faucet and
was connected to the device. The diverter could be set to
receive water through the treatment device (treated water) or
directly through the kitchen faucet (untreated water).
Sham devices were identical to active devices in every
respect but had an empty filter chamber, and the ultraviolet
bulb was surrounded by an ultraviolet absorbing glass sleeve
instead of the quartz sleeve present in the active devices.
Am J Epidemiol 2005;161:472–482

This sleeve effectively blocks transmission of radiation
while providing the same light and heat associated with
ultraviolet lamps surrounded by the quartz sleeve.
Study area

Several criteria were used to select the site: the community
had to receive drinking water from one microbiologically
challenged (i.e., with known upstream-contaminated
discharges containing human waste) surface water (river)
source; the source water had to be treated at one water treatment plant; the water had to be treated by conventional
drinking water treatment methods to meet all US microbial
regulatory standards (10–12); and the community had to be
large enough so that we could recruit 400 households for a
study (estimated to be about 100,000 households based on
participation rates in prior trials) (3–6). An additional
consideration was the willingness of the utility to provide
data on treatment performance. The source water for the
study site was one of the most contaminated of among 300
systems on which pathogen data were available (13).
Finding a study site that could provide useful data as one
piece of information in the development of a national estimate of disease occurrence was a key concern in developing
and weighing the importance of the different selection
criteria. The goal was to select a system “typical” of the type
that serves a large percentage of the US population (e.g., a
large system that complies with drinking water regulations),
and, recognizing that an affordable-size study would be able
to detect only a large fraction of illness, such as measured in
prior Canadian studies (3, 4), it was important that the
system be subject to a high level of microbial risk (i.e., a
system with extremely challenged source water). Other
studies conducted at other sites in the United States with
different water treatment characteristics would be needed to
fully estimate a national attributable risk.
Numerous municipalities were considered by the CDC,
the EPA, and our team. Ultimately, the Davenport/Bettendorf area of Scott County, Iowa, best fulfilled these criteria.
The trial was performed in the cities of Davenport and
Bettendorf and the associated neighboring communities of
Panorama Park and Riverdale, all located in Scott County,
Iowa, and served by the Iowa American Water Company.
Municipal water supply and treatment

The residents in the study area received their municipal
water from a single source, the Mississippi River, which is
treated at a single plant. Extensive monitoring for pathogens
and indicators of fecal contamination conducted by the local
water utility from 1990 to 1998 indicated that the Mississippi
River at Davenport was a challenged source with evidence of
human fecal contamination (14). Sampling during the time
of the trial showed similar levels (data available on request
from the authors). Finished water consistently met all state
and federal standards for the year prior to the trial and during
the trial. The utility is also one of a select group of utilities
that have received the Directors’ Award from the Partnership
for SafeWater (an organization founded by EPA, state regulators, and the drinking water industry) for their efforts to
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We report here the results of the Water Evaluation Trial, a
full-scale trial designed after a pilot trial was completed (6).
This full-scale trial was a randomized, controlled, tripleblinded, crossover intervention study performed in Davenport, Iowa, and its surrounding communities along the
Mississippi River. The principal objective was to measure
the change in the incidence of gastrointestinal illness from
use of supplemental in-home drinking water treatment by a
healthy population consuming tap water. This tap water was
supplied by a municipal system using conventional treatment methods to purify microbiologically contaminated
river water while maintaining the system to meet all current
US regulatory standards.
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produce water that exceeds current regulatory filtration
performance standards (15, 16).
The water utility uses “conventional” treatment consisting
of coagulation, flocculation, sedimentation, filtration through
granular activated carbon/sand filters, and chlorination. Granular activated carbon is used as a combination filtration/
adsorption medium to remove organics and to treat objectionable tastes and odors (refer to the following website:

www.iawater.com). Treatment performance and management
of the distribution system during the intervention trial period
are discussed in detail in a separate report (17).
Recruitment and enrollment

Recruitment began on October 16, 2000. The eligible
population consisted of households served by the Iowa
Am J Epidemiol 2005;161:472–482
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FIGURE 1. Flow chart of the random assignment, crossover, and completion of 456 households enrolled in a randomized controlled trial of an
in-home drinking water intervention in Davenport, Iowa, and neighboring communities, October 2000–May 2002.
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TABLE 1. Baseline characteristics of 1,296 participants
enrolled in the Water Evaluation Trial, a randomized controlled
trial of an in-home drinking water intervention in Davenport,
Iowa, and neighboring communities, October 2000–May 2002

Characteristic

Active-device
group
(n = 646)
%

No. of
persons

%

Characteristic

Active-device
group
(n = 646)
No. of
persons

%

Sham-device
group
(n = 650)
No. of
persons

%

History of vomiting
Frequently

3

0.5

Occasionally

241

4

1
37

246

38

Never

400

62

398

61

1

0.2

3

0.5

4

1

Gender (% male)

320

50

324

50

Currently in school

215

33

242

37

Currently working

342

53

345

53

1

26

11

30

13

2

88

39

87

38

3

42

19

46

20

4

46

20

38

17

5

17

7

17

7

6

7

3

9

4

7–9

1

0.4

2

0.9

Excellent

224

35

230

35

Very good

255

39

253

39

1–5

335

52

315

48

Good

135

21

137

21

6–10

232

36

245

38

Fair

28

4

22

3

11–15

35

5

26

4

Poor

3

0.5

5

1

16–20

5

1

2

0.3

Missing

1

0.2

3

0.5

!20

2

0.3

3

0.5

72

11

85

13

Missing

History of diverticulitis

14

2

15

2

Irritable bowel syndrome

30

5

34

5

23

4

27

4

Occasionally

326

50

351

Never

294

46

267

3

0.5

5

No. of persons in the household

Self-reported health

History of heartburn

Missing

Fever
Frequently

2

0.3

Occasionally

332

51

349

54

Never

305

47

294

45

Missing
Any current medication use
Pregnant at enrollment

2

0

14

2

9

1

<1

5

1

5

1

45

7

0

20

3

22

3

<1

15

2

11

2

54

1–5

409

63

397

61

41

6–10

151

23

152

23

1

11–15

18

3

10

2

16–20

1

0.2

1

0.25

1

0.2

1

0.2

Self-estimated daily water
consumption* (home only)

!20

Occasionally

335

52

369

57

Missing

Never

293

45

255

39

1

0.2

4

1

History of nausea
10

2

Occasionally

294

46

321

49

Never

336

52

317

49

6

1

5

1

1

Table continues

31

5

56

9

0

505

78

513

79

<1

31

5

23

4

1–5

63

10

54

8

6–10

6

1

5

1

11–15

0

0

0

0

16–20

0

0

0

0

!20

1

0.2

1

0.2

Self-estimated daily bottled water
consumption*

Missing

American Water Company in the communities of Davenport, Bettendorf, Riverdale, and Panorama Park. Apartments
were excluded because of concern that their water may not
be representative of the water in the community because of
the potentially increased risk of plumbing cross-connections
within apartment buildings. The water utility provided a list
of all 40,403 residential service addresses. Of these, 2,050
addresses with post office boxes (likely to be businesses or
Am J Epidemiol 2005;161:472–482

43

Self-estimated total daily water
consumption*

3

Missing

1

5

22

7

279

2

3

Frequently

41

5

5

17

Missing

266

1

3

History of diarrhea
Frequently

5

18

History of cramps
Frequently

Missing

40

6

54

8

* Number of 8-ounce (240-ml) glasses.

apartments), out-of-service addresses, addresses outside the
study area, and apartment numbers were excluded. Solicitations for enrollment were sent to the remaining 38,353
addresses in randomly selected blocks, taking a proportionate number of addresses from each ZIP Code between
October 16, 2000, and January 25, 2001.
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No. of
persons

Sham-device
group
(n = 650)

TABLE 1. Continued
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TABLE 2. Daily average water consumption* by participants enrolled in the Water Evaluation Trial, a randomized controlled trial of an
in-home drinking water intervention in Davenport, Iowa, and neighboring communities, October 2000–May 2002
Active device

Sham device
p value†

Minimum

25% IQR‡

Median

75% IQR

Maximum

Minimum

25% IQR

Median

75% IQR

Maximum

Cycle 1

0

5.1

9.4

17.9

75.7

0

5.5

8.5

16.2

57.8

0.34

Cycle 2

0

3.0

6.4

11.5

47.2

0

2.1

6.0

11.5

46.8

0.69

The mailing provided information about the study, with a
toll-free telephone number and a postcard. Households were
excluded if they contained an employee of the Iowa American Water Company, had an address outside the local utility
water service area, consumed less than 75 percent of their inhome drinking water from the tap, contained an immunocompromised person (including one with human immunodeficiency virus or active cancer under treatment), or included
any member who had been advised by a physician to drink
only bottled or specially treated water.
For each participant, the entire trial was 54 weeks long (26
weeks during cycle A, a 2-week washout period, and 26
weeks during cycle B). During the washout period, participants used no device but continued to complete health
diaries. The length of the washout period was chosen to be
longer than the symptomatic period of most likely infectious
causes of gastrointestinal illness (18). Enrollment was
completed on May 30, 2001, with a final enrollment of 456
households and 1,296 individual persons.
Randomization and (triple) blinding

Households were randomly assigned by block in blocks of
14 with equal probability to receive either an active or a
sham device. A randomized list of device assignment codes
was prepared by an unblinded staff member not involved
with installation or analysis and was sent to the manufacturer. Device assignments were hidden from the investigators and installers, the study subjects, and the data analysts.
All analyses were conducted by using a noninformative code
for device type. Investigators remained blinded to household
assignment until after all analyses were completed and finalized and the first draft of this manuscript had been written
and circulated. Households contacted the research center or
returned postcards to participate. After consent forms were
returned, randomly assigned devices were allocated from an
offsite list.
Health outcomes

Adult household members recorded daily occurrences of
illness in their health diaries. An adult member recorded
responses for children under age 12 years. The principal
health outcome measured was episodes of “highly credible
gastrointestinal illness” (HCGI), a previously published
measure (3–6). A new episode was defined as any of the

following four conditions, preceded by at least six HCGIfree days: 1) vomiting, 2) watery diarrhea, 3) soft diarrhea
and abdominal cramps, or 4) nausea and abdominal cramps.
The requirement for six disease-free days between episodes
was used to increase the likelihood that separate episodes
truly represented distinct infections (rather than a prolonged
course of one infection) (3–6).
Statistical methods
Blinding Index. Blinding was measured by using the
“Blinding Index” of James et al. (19). Full details on its use
in a drinking water intervention trial were reported in the
pilot study (6).
Analysis of HGCI. The primary statistical analysis
presented in this paper evaluated the effect of in-home water
treatment on two individual-level outcomes: counts of the
numbers of episodes of HCGI (the primary outcome of the
study) and counts of the days (a prespecified secondary
outcome) during each treatment cycle. We denote the
outcome as Yi,j, the number of person-years of observation
time as Ti,j , and ai,j as the treatment assignment for the ith
individual during the jth cycle. The treatment variable ai,j = 0
if the individual was in a household receiving the active
device during the jth cycle; otherwise, ai,j = 1. For the initial
6-month observation period (cycle A), we let j = 0, while,
after the crossover, j = 1.
To estimate a treatment effect that can take into account
both a cycle effect (before vs. after crossover) and a treatment-by-cycle interaction, we fit a log-linear generalized
estimating equation model (20). This statistical model is
appropriate for correlated count outcomes that may exhibit
extra-Poisson variability. Using this approach, we modeled
the log of the mean incidence rate for each individual
measurement as follows: log E(Yi,j) = E0 + log Ti,j + E1j +
E2ai,j + E3jai,j.
Here, E1 is the period effect, E2 is the effect of drinking
untreated tap water, and E3 is a treatment-cycle interaction.
The parameter estimates are interpreted as being the
change in a marginal log rate. For example, the parameter
exp(E2) can be interpreted as the ratio of the average rate of
illness for an individual from an untreated household to the
average rate of illness for an individual from a treated
household during the first cycle. The effect of drinking
untreated water during the second cycle is given by
exp(E2 + E3). For maximal statistical efficiency, we used a
Am J Epidemiol 2005;161:472–482
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* Number of 8-ounce (240-ml) glasses per day as measured by an electronic totalizer.
† p value for a two-sided t test comparing sham- with active-device water usage during each cycle of the study.
‡ IQR, interquartile range.
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TABLE 3. Blinding, by device type, of participants enrolled in the Water Evaluation Trial, a randomized
controlled trial of an in-home drinking water intervention in Davenport, Iowa, and neighboring
communities, October 2000–May 2002
Cycle, month,
and guess

Active device

Sham device

Overall

No.

%

No.

%

No.

%

Active device

140

31

122

28

262

29

Sham device

43

9

64

14

107

12

271

60

258

58

529

59

Active device

117

27

95

23

212

25

Sham device

44

10

41

10

85

10

278

63

275

67

553

65

Active device

49

13

39

10

88

12

Sham device

56

15

70

19

126

17

272

72

265

71

537

71

Active device

50

14

32

9

82

11

Sham device

39

11

64

17

103

14

271

75

278

74

549

75

Blinding
Index
(entire cycle)

95%
confidence
interval

0.77

0.74, 0.80

0.82

0.79, 0.85

0.84

0.82, 0.87

0.85

0.82, 0.87

Cycle 1

Don’t know
Last month

Don’t know
Cycle 2
First month

Don’t know
Last month

Don’t know

working correlation matrix with a structure that accounted
for both within-subject and within-household correlation.
The standard errors of the parameter estimates are
computed robustly and are asymptotically valid when the
empirical variance-covariance matrix is used (20). Diggle
et al. (21) illustrated the use of the generalized estimating
equation approach to analyze data from a crossover trial
with a dichotomous outcome.
Data (prior to dropout) from households that dropped out
of the trial at any point after randomization were retained
(intention-to-treat analysis).
Water consumption (exposure measurement)

Water consumption (i.e., the degree of exposure to the
intervention) was measured in two ways. First, self-reported
data were collected from participants by using questions
inserted into the health diary at 2-week intervals. Participants estimated (in numbers of 8-ounce (240-ml) glasses)
their daily consumption of drinking water at home (separately through the study device and through all other sources
at home) and outside the home. Additionally, an electronic
flow meter (a totalizer) had been installed in each device to
measure the amount consumed and the time at which water
was used.
Participants were provided with water bottles and were
encouraged to carry water from the home device when
outside the home. Mean water consumption was compared
by study group using the two-sample t test.
Am J Epidemiol 2005;161:472–482

RESULTS
Recruitment, enrollment, withdrawals, and completion

As detailed in the flow chart shown in figure 1, we screened
1,421 households that responded to our request for participation. Of these, 687 (48 percent) were eligible. We enrolled
456 households (1,296 individual persons) to meet our goal
of 400 households (estimated to enable us to detect a relative
rate of 1.15 with 80 percent power). The overall completion
rates for the entire study were 82 percent for those originally
assigned randomly to the active device group and 86 percent
for those originally assigned randomly to the sham device
group, resulting in complete 1-year follow-up for 84 percent
of those initially enrolled. The most frequent reasons given
for dropping out are detailed in figure 1.
Baseline characteristics of participants and
completeness of data collection

Random assignment appeared to be successful, and participants in the groups were well balanced at baseline with
respect to numerous factors (table 1). The median age of
participants in the active group was 33 years (interquartile
range, 13–47 years); those in the sham group were a median
age of 32 years (interquartile range, 13–49 years).
Water consumption (exposure) patterns during the trial

Participants estimated how many 8-ounce glasses of
unheated bottled water (all types) they drank each day (data

Downloaded from https://academic.oup.com/aje/article/161/5/472/108267 by University of Nebraska Medical Center user on 23 December 2021
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TABLE 4. Episodes and days of illness, by device and cycle, for participants enrolled in the Water
Evaluation Trial, a randomized controlled trial of an in-home drinking water intervention in Davenport,
Iowa, and neighboring communities, October 2000–May 2002
Cycle A
Event

Cycle B
Sham
device

Active
device

Sham
device

Highly credible gastrointestinal illness

707

672

516

476

Diarrhea*

208

208

186

142

Watery diarrhea†

138

147

131

103

Vomiting

214

196

170

175

Any watery diarrhea

407

391

300

269

Soft diarrhea and cramps

154

136

94

88

Nausea and cramps

217

220

186

171

Highly credible gastrointestinal illness

1,423

1,585

977

929

Diarrhea

381

508

283

215

Watery diarrhea

227

394

182

152

Vomiting

288

299

261

241

Any watery diarrhea

774

921

494

538

Soft diarrhea and cramps

281

227

128

121

Nausea and cramps

380

458

386

313

Days of work or school missed

221

209

269

239

Visited physician for gastrointestinal illness

20

12

9

14

Person-years at risk for highly credible gastrointestinal
illness

292.58

280.57

263.26

260.83

Person-years at risk for missing work or school

229.43

224.24

221.30

212.86

Episodes of illness

Days of illness

Measures of disease impact

Years at risk

* Reported three or more instances of diarrhea during the day.
† Reported three or more instances of diarrhea and indicated that diarrhea was watery.

not shown). Water consumption between the two groups
appeared similar with respect to the amount of bottled water
or untreated tap water consumed at or away from home. An
electronic totalizer in each of the devices recorded no significant difference between the two groups (table 2).
Effectiveness of blinding of participants

The data gathered during the first and last months of each
of the two 6-month cycles are presented in table 3 and
suggest that blinding was maintained throughout the trial.
The Blinding Index (values greater than 0.50 are consistent
with successful blinding (6, 19)) increased slightly from 0.77
in the first month to 0.85 by the 12th month.
Analysis of gastrointestinal illnesses

The principal outcome of the trial was episodes of HCGI.
During cycle A, 707 episodes were reported by active-device
participants, and 672 episodes were reported by sham-device
participants (table 4). During cycle B, 516 and 476 episodes

were reported in the active and sham device groups, respectively.
We also compared the groups with respect to differences
in days of HCGI (table 4). Again, no significant differences
between the groups were found.
We evaluated the risk of HCGI episodes for the activedevice group versus the sham-device group (the a priori
study goal) during the entire study by using the generalized
estimating equation model described above. In addition to
the full model, we examined models without the interaction
term and with only the device term (table 5). The full model
suggested no device effect nor any cycle-by-device interaction, indicating that the device yielded no reduction in the
relative rate of HCGI for either cycle A or cycle B. The final
model provided a relative rate estimate (sham-device vs.
active-device group) of 0.98 (95 percent confidence interval
(CI): 0.86, 1.10). Similar analyses were conducted with the
outcome defined as days of HCGI and suggested no significant effect of the device (table 5).
Although our trial was randomized (which ideally will
balance the distribution of known and unknown confounding
factors across the two arms of the study), we also conducted
Am J Epidemiol 2005;161:472–482
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TABLE 5. Multivariate models for episodes and days of highly credible gastrointestinal illness using generalized estimating
equations analysis for a sham vs. an active device among participants enrolled in the Water Evaluation Trial, a randomized controlled
trial of an in-home drinking water intervention in Davenport, Iowa, and neighboring communities, October 2000–May 2002
Analysis
Episodes of highly credible gastrointestinal illness

95%
confidence
interval

p value

Device (sham vs. active)

0.98

0.78, 1.22

0.83

Cycle (B vs. A)

0.75

0.59, 0.97

0.03

Cycle u device

1.00

0.64, 1.55

0.98

Device (sham vs. active)

0.98

0.87, 1.10

0.66

Cycle (B vs. A)

0.75

0.67, 0.85

<0.001

Device only

Device

0.98

0.86, 1.10

0.70

Interaction

Device (sham vs. active)

1.11

0.78, 1.57

0.58

Cycle (B vs. A)

0.66

0.48, 0.92

0.01

Cycle u device

0.98

0.56, 1.71

0.94

Device (sham vs. active)

1.10

0.87, 1.38

0.44

Interaction

No interaction

Days of highly credible gastrointestinal illness

No interaction

Parameter

Cycle (B vs. A)
Episodes of highly credible gastrointestinal illness
adjusted for additional covariates

<0.001

Device only

Device (sham vs. active)

1.10

0.86, 1.41

0.44

Multivariate

Device

0.96

0.85, 1.08

0.47

Cycle (B vs. A)

1.19

1.05, 1.35

<0.01

Age (per year)

1.00

0.99, 1.00

0.14

Total water consumption (per 8ounce* glass)

1.01

1.00, 1.44

0.11

Female vs. male gender

1.25

1.09, 1.44

<0.01

Summer

1.93

1.63, 2.30

<0.01

Fall

0.64

0.49, 0.84

<0.01

Winter

2.48

2.12, 2.90

<0.01

Season (vs. spring)

* 8 ounces = 240 ml.

multivariate analyses to adjust for potential confounding by
season, gender, water consumption, and age on the effect of
the device on episodes of HCGI. The effect of the device
remained unchanged (relative rate = 0.96, 95 percent CI:
0.85, 1.08) in these analyses. An additional model (not
shown) adjusting for these same variables and for the
proportion of water consumed outside the home (rather than
for total water consumption) yielded no change in the
conclusion about the effect of the device (relative rate =
0.96, 95 percent CI: 0.85, 1.08).
We also analyzed the correlation of outcomes within
person and within household during the study. Within
person, the correlation of HCGI was 0.68. Within household
(within the same cycle), the correlation was 0.241. Within
household (in a different cycle), the correlation was 0.239
for HCGI.
We investigated the possibility that the device effect might
vary within different subgroups of age, gender, employment
status, water consumption, and completeness of participation
(table 6). In none of these analyses did we detect any significant differences.
Adverse events

Six deaths occurred (two while in the active-device group
and four while in the sham-device group). Causes of death
Am J Epidemiol 2005;161:472–482

included one case each of suicide, cardiopulmonary arrest,
cancer, myocardial infarction, pneumonia, and bacterial
sepsis. Thirty hospitalizations were reported by participants
during the trial (18 while in the active-device group and 12
while in the sham-device group). None of the deaths and
none of the hospitalizations were believed to be trial related.
DISCUSSION

To our knowledge, this randomized trial of in-home
drinking water intervention is the largest conducted in the
United States and the first to measure exposure (i.e., device
usage) electronically (prior studies relied exclusively on
self-reported usage). Our results suggest no significant
decrease in the incidence of gastrointestinal illness among
immunocompetent persons from using an in-home drinking
water treatment device with combined 1-Pm filtration and
ultraviolet light. A water treatment device with a 1-Pm absolute filter is highly effective in removing Giardia,
Cryptosporidium, and other similarly sized microorganisms
that can cause gastrointestinal illness. Prior testing of the
device’s ultraviolet treatment unit demonstrated a 99.99
percent inactivation of viruses (22).
In 1991, Payment et al. (3) published the results of the first
randomized, controlled drinking water intervention trial
using reverse osmosis filtration in a system with a chal-
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TABLE 6. Subgroup analyses of relative rate (sham vs. active
device), using generalized estimating equations episodes, of
highly credible gastrointestinal illness among participants
enrolled in the Water Evaluation Trial, a randomized controlled
trial of an in-home drinking water intervention in Davenport,
Iowa, and neighboring communities, October 2000–May 2002
95%
confidence
interval

Weeks 1–18

1.01

0.87, 1.18

Weeks 19–36

0.94

0.79, 1.12

Weeks >36

0.98

0.82, 1.17

Low (0–2.08)

0.88

0.72, 1.08

Medium (2.09–3.54)

0.97

0.82, 1.16

High (>3.54)

1.00

0.85, 1.17

Male

0.95

0.83, 1.08

Female

0.98

0.87, 1.09

0–5

1.13

0.89, 1.43

6–20

0.87

0.72, 1.04

21–49

0.95

0.83, 1.08

>49

0.97

0.81, 1.17

Full-time job

1.00

0.82, 1.23

Part-time job

0.86

0.57, 1.28

None

0.91

0.69, 1.19

Time in study

Water consumption (8-ounce* glasses
per day)

Gender

Age (years)

Employment status

* 8 ounces = 240 ml.

lenged source water. Filters were installed in 299 households
(including 1,206 individual persons), and another 307 households (1,202 individuals) were followed as controls (no
device installed). During a 15-month period, these investigators concluded that 35 percent of the self-reported
gastrointestinal illness was attributable to tap water.
Subsequently, Payment et al. (4) conducted a second
drinking water trial that included treatment groups receiving
regular tap water, tap water from a continuously purged tap,
bottled treatment plant water, or purified bottled plant water
in a system that met all Canadian and equivalent US water
microbial treatment standards. This study, conducted in the
same community as the first trial, concluded that 14–40
percent of gastrointestinal illness could be attributed to tap
water, depending on the comparison group. Participants in
the first study and in the two groups in the second study who
did not receive bottled water were not blinded to their treatment assignments. Although bottled water recipients were
not informed of their group assignment, 50 percent of those
receiving bottled water from the treatment plant withdrew
from the trial, citing taste and odor problems. No significant
difference in gastrointestinal illness rates was observed
between the two groups drinking bottled water. The only
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relative rate

Subgroup

significant differences were observed between the bottled
water and the tap water groups. The authors noted that it was
possible that reporting of gastrointestinal illness could have
been affected by this lack of blinding. In our study, there was
strong evidence, measured by the Blinding Index, that participants were successfully blinded. In both Payment studies (3,
4), the source water was contaminated by sewage and other
materials, similar to the setting in which our trial was
conducted.
In a randomized, controlled, drinking water trial in
Australia, Hellard et al. (5) reported no difference in the rates
of illness between sham and active treatment groups. A sham
device was used in the Australian trial to blind participants,
as in our trial. In the Australian trial, the source water was
reported to be of high quality, from protected catchments
unaffected by human activity, which differs markedly from
the challenged source (Mississippi River) water used in our
study.
Recently, our group published results from a randomized,
controlled trial in Walnut Creek, California, among households consuming water from a contaminated source that was
conventionally treated to meet all US federal standards (6).
This trial confirmed that blinding of participants could be
maintained successfully during such a drinking water study.
Although the point estimate of the effect in the pilot trial
(relative rate = 1.32, 95 percent CI: 0.75, 2.33) was consistent with the point estimate reported in the prior Payment
studies (3, 4), this study was not large enough to be likely to
detect a statistically significant effect.
The primary health outcome was episodes of HCGI,
chosen both because of its high sensitivity (any of several
different symptoms constitute an episode) and because of its
use in prior trials (3, 5, 6). In an effort to be specific about
significant illness, we also measured days lost from work or
school. We found no significant differences between the
devices within either cycle or over the entire trial.
We measured as a secondary (but specified a priori)
outcome total days of HCGI. This measure was intended to
provide a sense of the burden of illness in the two groups.
Again, no differences between the groups were found.
Using data on water usage from the device reported by
participants, we found no difference between groups with
respect to use of the device during either cycle of the trial.
Analysis of the data from the electronic totalizer in each
device supported this finding, which suggests that our findings are not attributable to differential exposure to the
untreated municipal water.
We noted a decline in the frequency of HCGI episodes
over time in both groups (figure 2) very similar to that
reported by others (3, 5). Although HCGI does have a strong
seasonal component (table 5), we hypothesize that the
decline seen during cycle 2 (equal in both groups) is more
likely due to a loss of enthusiasm for reporting illness. Half
of the subjects were randomly assigned to the active device
in cycle 1 and the other half to the inactive device, and the
decline in reporting was equivalent in the two arms. We also
noted a strong effect of cycle (table 5). Because of the twoperiod crossover study design, cycle effects were not likely
to bias the principal relation between device and HCGI, and
there is no evidence that they did bias this relation (table 5).
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The correlation of HCGI within households was essentially identical both within the same cycle (0.241) and across
the different cycles (0.239) of the study. This consistency
across the different cycles (which could be detected with
only a crossover design) suggests that secondary transmission is not as important within a household as are other
factors related to gastrointestinal illness. If true, the presence
of other factors associated with gastrointestinal illness
within a family highlights the importance of random assignment of households in such studies.
We examined the possibility that the effect of the device
might differ within important subgroups defined by age
(prior studies had reported such differences (23)), length of
participation, level of use of the device (i.e., a type of dose
response), gender, or employment status. In none of these
subgroup analyses was a significant effect detected (table 6).
We considered the possibility that the lack of an observed
effect of the device may have been attributable to use of
water outside the home. This possibility would have had the
effect of attenuating any true effect the device may have had
in reducing illness. We examined the device effect for only
those subjects who reported that 90 percent or more of their
water consumption was from the device (relative rate = 1.08,
95 percent CI: 0.85, 1.37), suggesting that the results were
not likely explained by water consumption outside the home.
Our trial has limitations. It is possible that subjects in both
groups, faced daily with the device, were reminded
constantly about the study and altered their behavior or
Am J Epidemiol 2005;161:472–482

illness reporting in unknown ways so as to change their incidence of reporting of gastrointestinal illness (and thus drive
the results toward a null effect). We have no data to evaluate
this possibility. In future trials, a third, unblinded group of
subjects with no device could be enrolled as an additional
comparison group, but such data might be difficult to interpret because of a lack of blinding. It is possible that any true
device effect was too small to be detected by the study. Since
subjects drank water away from home and were exposed to
pathogens in food, water, and other sources, it is possible
that any reduction in the incidence of gastrointestinal illness
attributable to the device could not be detected by the study
because of its size. The confidence interval in the Australian
trial indicated that less than 15 percent of gastrointestinal
illness is likely caused by drinking water (5); this finding is
very similar to our results suggesting that less than 11
percent of gastrointestinal illness is likely attributable to
drinking water. Our study was not designed to address
important questions about risk in immunocompromised
persons. Studies suggest that human immunodeficiency
virus-positive persons may be more susceptible to some
waterborne infections during both outbreak situations and
times without any known outbreak under way (24–27).
Finally, because our study was conducted in a community
with documented high standards of water quality treatment
(refer to the Materials and Methods section), the generalizability of our results to other communities with different
treatment efficiencies cannot be determined with our data.
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FIGURE 2. Weekly rates of “highly credible gastrointestinal illness (HCGI) after enrollment of 1,296 participants in a randomized controlled trial
of an in-home drinking water intervention in Davenport, Iowa, and neighboring communities, October 2000–May 2002.
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